Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 3/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 3/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | LTK | P29376 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448937 | 1.00 | NTRK1 (1.00) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL5472269 | 1.00 | NTRK1 (1.00) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL14448939 | 0.91 | NTRK1 (0.83) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL5473052 | 0.91 | NTRK1 (0.83) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL5473050 | 0.91 | NTRK1 (0.83) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL7780481 | 0.91 | NTRK1 (0.83) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL14448947 | 0.86 | NTRK1 (0.76) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL5470617 | 0.86 | NTRK1 (0.76) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL5470614 | 0.86 | NTRK1 (0.76) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 | |
| SCHEMBL5203073 | 0.86 | NTRK1 (0.75) | NTRK1CSNK1A1NTRK3NTRK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| EP-0987263-B1 | Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors | PFIZER ITALIA SRL (IT) | 2007-04-18 | — | — | EP | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| EP-0987263-A2 | Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-03-22 | — | — | EP | claimed |
| US-5656654-A | TYROSINE KINASE INHIBITORS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1997-08-12 | — | — | US | claimed |
| US-20170057948-A1 | INDOLE-LIKE TRK RECEPTOR ANTAGONISTS | UNIVERSITY OF TARTU (EE) | 2017-03-02 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| EP-0987263-B1 | Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors | PFIZER ITALIA SRL (IT) | 2007-04-18 | — | — | EP | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
| EP-0987263-A2 | Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-03-22 | — | — | EP | disclosed |
| US-5656654-A | TYROSINE KINASE INHIBITORS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1997-08-12 | — | — | US | disclosed |
| EP-0658159-A1 | ARYLIDENE AND HETEROARYLIDENE OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1995-06-21 | — | — | EP | disclosed |
| WO-1995001349-A1 | ARYLIDENE AND HETEROARYLIDENE OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA S.P.A. (IT) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057948-A1 | INDOLE-LIKE TRK RECEPTOR ANTAGONISTS | NTRK3, NTRK1, MUSK | NTRK1 2/4885CSNK1A1 59/4885NTRK3 1/4885 |
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | NTRK1 175/4885CSNK1A1 3608/4885NTRK3 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.